diaDexus
South San Francisco
About diaDexus
diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. The company's lead product, the PLAC Test, measures Lp-PLA2 (lipoprotein-associated phospholipase A2) a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiovascular events. The PLAC Test is the only blood test cleared by the FDA as an aid in assessing risk for coronary heart disease, and ischemic stroke associated with atherosclerosis.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $171.2M
- Funding stage: M&A
- Last round: Post-IPO Debt (Aug 2014)
- Ticker: otcqb:DDXS
- Website: diadexus.com
- Phone: 6502466400
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/diadexus-2936698 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.